Once-monthly efimosfermin demonstrated statistically significant fibrosis improvement ≥1 stage without worsening of MASH vs. placebo after 24-weeks of treatment Two-thirds of efimosfermin-treated ...

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial ...

Terns Pharmaceuticals announced significant updates regarding TERN-601, a novel oral GLP-1R agonist, following a successful Phase 1 clinical study and the completion of enrollment in its Phase 2 ...

BriaCell (BCTX) Therapeutics presents positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium, SABCS, taking place December ...

Cidara Therapeutics soared 250% after strong Phase 2b NAVIGATE trial results for CD388, a novel antiviral for flu prophylaxis. CD388 demonstrated up to 76% efficacy, outperforming many traditional flu ...